Abstract
As explorations deepen, the role of microRNAs (miRNAs) in lung squamous cell carcinoma (LUSC), from its emergence to metastasis and prognosis, has elicited extensive concern. LUSC-related miRNA and mRNA samples were acquired from The Cancer Genome Atlas (TCGA) database. The data were initially screened and pretreated, and the R platform and series analytical tools were used to identify the specific and sensitive biomarkers. Seven miRNAs and 15 hub genes were found to be closely related to the overall survival of patients with LUSC. Determination of the expression of these miRNAs can help improve the overall survival of LUSC patients. The 15 hub genes correlated with overall survival (OS). The new miRNA markers were identified to predict the prognosis of LUSC. The findings of this study offer novel views on the evolution of precise cancer treatment approaches with high reliability.
Highlights
IntroductionOne of the most serious malignancies, is the primary cause of cancer-related deaths worldwide [1]
Lung carcinoma, one of the most serious malignancies, is the primary cause of cancer-related deaths worldwide [1]
For prognostic screening of miRNAs, Cox regression analysis was used to verify the characteristics of miRNAs with different expression levels
Summary
One of the most serious malignancies, is the primary cause of cancer-related deaths worldwide [1]. Radiation therapy and targeted therapy do not considerably improve the patient’s survival, and the overall 5-year survival rate remains below 20% [3]. Lung squamous carcinoma (LUSC) is a common histologic subtype of lung cancer characterized by atypical early symptoms and inherent resistance to radiation and chemotherapy. The lack of appropriate targeted drugs has led to a poorer prognosis of LUSC compared with lung adenocarcinoma [4]. Traditional methods are unable to accurately assess the prognosis of patients with LUSC. Identifying the prognostic markers and establishing new and reliable prognostic models are crucial for enhancing the quality of life, prognosis, and overall survival (OS) of LUSC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
